We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current PHARM market cap is 581.51M. The company's latest EPS is USD -0.0163 and P/E is -55.21.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 169.02M | 212.17M | 198.87M | 205.62M | 245.32M |
| Operating Income | 61.14M | 76.62M | 14.26M | 17.09M | -5.68M |
| Net Income | 36.2M | 37.75M | 16M | 13.67M | -10.55M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 228.21M | 418.45M | 397.32M | 425.8M | 462.85M |
| Total Liabilities | 123.53M | 235.02M | 204.4M | 221.16M | 244.07M |
| Total Equity | 104.68M | 183.44M | 192.92M | 204.64M | 218.78M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 66.5M | 83.63M | 37.84M | 22.46M | -17.3M |
| Investing | -25.22M | -15.63M | -21.31M | 5.32M | -129.39M |
| Financing | -56.65M | 60.69M | -27.95M | -4.98M | -1.04M |
| Market Cap | 581.51M |
| Price to Earnings Ratio | -55.21 |
| Price to Sales Ratio | 2.37 |
| Price to Cash Ratio | 9.41 |
| Price to Book Ratio | 2.66 |
| Dividend Yield | - |
| Shares Outstanding | 646.12M |
| Average Volume (1 week) | 6.1M |
| Average Volume (1 Month) | 7.27M |
| 52 Week Change | -9.82% |
| 52 Week High | 1.313 |
| 52 Week Low | 0.861 |
| Spread (Intraday) | 0 (0.39%) |
| Company Name | Pharming Group NV |
| Address |
vondellaan 47 leiden, south holland 2332 AA |
| Website | https://www.pharming.com |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
